MedTrace Logo

Study In People With Type 2 Diabetes

NCT00196989 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 448

Last updated 2017-03-23

No results posted yet for this study

Summary

This Phase 2 dose-ranging study will evaluate the efficacy, safety and tolerability of a range of doses of GW677954 compared with placebo over sixteen weeks of treatment in subjects with T2DM (Type 2 Diabetes Mellitus).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Pioglitazone

DRUG

GW677954

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-04-30
Completion
2007-04-30

Countries

  • United States
  • Argentina
  • Australia
  • Canada
  • Colombia
  • Costa Rica
  • Czechia
  • Ecuador
  • Latvia
  • Mexico
  • New Zealand
  • Peru
  • Russia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00196989 on ClinicalTrials.gov